Show simple item record

dc.contributor.authorSantoro, Matteo
dc.contributor.authorMaetzler, Walter
dc.contributor.authorStathakos, Petros
dc.contributor.authorMartin, Heather L.
dc.contributor.authorHobert, Markus A.
dc.contributor.authorRattray, Tim W.
dc.contributor.authorGasser, Thomas
dc.contributor.authorForrester, John V.
dc.contributor.authorBerg, Daniela
dc.contributor.authorTracey, Kevin J.
dc.contributor.authorRiedel, Gernot
dc.contributor.authorTeismann, Peter
dc.date.accessioned2016-03-29T15:00:05Z
dc.date.available2016-03-29T15:00:05Z
dc.date.issued2016-07
dc.identifier.citationSantoro , M , Maetzler , W , Stathakos , P , Martin , H L , Hobert , M A , Rattray , T W , Gasser , T , Forrester , J V , Berg , D , Tracey , K J , Riedel , G & Teismann , P 2016 , ' In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin ' , Neurobiology of Disease , vol. 91 , pp. 59-68 . https://doi.org/10.1016/j.nbd.2016.02.018en
dc.identifier.issn0969-9961
dc.identifier.otherPURE: 62868043
dc.identifier.otherPURE UUID: 81030cfb-7168-46c7-a10c-1ba70c51b88c
dc.identifier.otherScopus: 84962520475
dc.identifier.urihttp://hdl.handle.net/2164/5783
dc.descriptionAcknowledgements Samples were obtained from the Neuro Biobank of the University of Tuebingen, Germany (http://www.hih-tuebingen.de/nd/biobank/for-researchers/). This biobank is supported by the Hertie Institute and the DZNE. We are grateful to the staff of the Medical Research Facility for their help with the animal care. We thank Dr. Kinnari Sathe for her help with the experiments. We thank Claire A. Walker for assisting with western blot analysis. This study was supported by: Tenovus Scotland, Parkinson's Disease Foundation, Royal Society 2006/R1, NHS Endowment 14-42, and Wellcome Trust WT080782MF.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofNeurobiology of Diseaseen
dc.rights© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)en
dc.subjectParkinson's diseaseen
dc.subjectMPTPen
dc.subjectHigh-mobility group box 1en
dc.subjectreceptor for advanced glycation endproductsen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectWellcome Trusten
dc.subjectWT080782MFen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRC0321en
dc.titleIn-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/j.nbd.2016.02.018


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record